UK Supreme Court strikes down Re­gen­eron patents, open­ing door for Kymab

The UK Supreme Court has struck down a pair of Re­gen­eron patents, all but end­ing a le­gal dis­pute be­tween the large US biotech and an up­start British com­peti­tor that has raged since 2013.

In a 4-1 rul­ing, the judges held that the patents Re­gen­eron filed on a tech­nique nec­es­sary to make their an­ti­body-pro­duc­ing mice didn’t pro­vide enough in­for­ma­tion for an ex­pert in the field to re­pro­duce all the in­ven­tions cov­ered in the claim. The rul­ing over­turned an ap­pel­late court de­ci­sion that held in fa­vor of Re­gen­eron and against the Cam­bridge-based Kymab.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.